Announced Thu, 13 Aug, 2026 · 17:59 IST
Aurobindo Pharma files Q1FY27 earnings call transcript
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹1663.40
prior close
₹1662.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.2+0.2-1.0-2.2-1.1-2.3-3.3-2.5-2.7-0.7-0.2——
Up moveDown movePending
AI summary
Aurobindo Pharma Q1FY27: consolidated revenue up 16% YoY to Rs.9,150 cr, operating EBITDA Rs.1,924 cr at 21% margin after Rs.43 cr one-time hit. Formulation grew 17% to Rs.8,101 cr. PAT Rs.1,032 cr. Gross margin improved to 60.4% from 58.8%. Lannett acquisition completed, A1 Biochem CRO buy announced. FY27 guidance: double-digit revenue growth, EBITDA margin above 21%, absolute EBITDA over Rs.8,000 cr.
Likely market impact
Strong Q1 with margin improvement and completed Lannett deal supports growth outlook. FY27 guidance reiterated with potential upside from high-value businesses.